1. Home
  2. HZO vs CGEM Comparison

HZO vs CGEM Comparison

Compare HZO & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MarineMax Inc.  (FL)

HZO

MarineMax Inc. (FL)

HOLD

Current Price

$35.05

Market Cap

769.2M

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$13.77

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HZO
CGEM
Founded
1998
2016
Country
United States
United States
Employees
3385
N/A
Industry
Auto & Home Supply Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
769.2M
904.7M
IPO Year
1998
2020

Fundamental Metrics

Financial Performance
Metric
HZO
CGEM
Price
$35.05
$13.77
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$30.00
$30.13
AVG Volume (30 Days)
336.6K
881.8K
Earning Date
04-23-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,309,288,000.00
N/A
Revenue This Year
$3.67
N/A
Revenue Next Year
$4.01
$5.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.52
$5.68
52 Week High
$34.68
$16.74

Technical Indicators

Market Signals
Indicator
HZO
CGEM
Relative Strength Index (RSI) 64.63 42.75
Support Level $24.00 $12.41
Resistance Level N/A $16.21
Average True Range (ATR) 1.71 0.94
MACD 0.13 -0.16
Stochastic Oscillator 84.13 11.57

Price Performance

Historical Comparison
HZO
CGEM

About HZO MarineMax Inc. (FL)

MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S and international market.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: